The FDA, Juno Therapeutics, and the ethical imperative of transparency

Spencer Phillips Hey1, Aaron S Kesselheim1

  • 1Program on Regulation, Therapeutics, and Law (PORTAL), division of pharmacoepidemiology and pharmacoeconomics, Brigham and Women's Hospital, Boston, US Harvard Center for Bioethics, Harvard Medical School, Boston, US.

BMJ (Clinical Research Ed.)
|August 17, 2016
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos